Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor.
Edwin N NeumannTessa M BertozziElaine WuFiona SerackJohn W HarveyPamela P BrauerCatherine P PirtleAlissa CoffeyMichael HowardNikita KamathKenney LenzKenia GuzmanMichael H RaymondAhmad S KhalilBenjamin E DevermanEric Vallabh MinikelSonia M VallabhJonathan S WeissmanPublished in: Science (New York, N.Y.) (2024)
Prion disease is caused by misfolding of the prion protein (PrP) into pathogenic self-propagating conformations, leading to rapid-onset dementia and death. However, elimination of endogenous PrP halts prion disease progression. In this study, we describe Coupled Histone tail for Autoinhibition Release of Methyltransferase (CHARM), a compact, enzyme-free epigenetic editor capable of silencing transcription through programmable DNA methylation. Using a histone H3 tail-Dnmt3l fusion, CHARM recruits and activates endogenous DNA methyltransferases, thereby reducing transgene size and cytotoxicity. When delivered to the mouse brain by systemic injection of adeno-associated virus (AAV), Prnp -targeted CHARM ablates PrP expression across the brain. Furthermore, we have temporally limited editor expression by implementing a kinetically tuned self-silencing approach. CHARM potentially represents a broadly applicable strategy to suppress pathogenic proteins, including those implicated in other neurodegenerative diseases.
Keyphrases
- dna methylation
- poor prognosis
- genome wide
- platelet rich plasma
- binding protein
- gene expression
- gene therapy
- protein protein
- amino acid
- mild cognitive impairment
- long non coding rna
- white matter
- circulating tumor
- cancer therapy
- multiple sclerosis
- cell free
- low cost
- drug delivery
- blood brain barrier
- drug induced
- circulating tumor cells